Version May 2024
| • Age >60 years | |||
| • Serum lactate dehydrogenase concentration above normal | |||
| • Hemoglobin level <12.0 g/dL | |||
| • Ann Arbor stage III or IV | |||
| • Number of involved nodal areas >4 | |||
| One point is given for each of the above characteristics present in the patient with FL, for a total score ranging from zero to five. When applied to an international study of long-term survival in 4167 patients with FL diagnosed between 1985 and 1992 and treated without rituximab, the following three risk groups and their corresponding five- and 10-year OS were, as follows[1]: | |||
| Score | Risk group | Five-year OS, percent | 10-year OS, percent |
| 0 to 1 | Low risk | 91 | 71 |
| 2 | Intermediate risk | 78 | 51 |
| 3 or more | High risk | 52 | 36 |
| This same score was applied to 2192 patients diagnosed between 2004 and 2007, the majority of whom (68 percent) received rituximab in the initial management, with the following results[2]: | |||
| Score | Two-year OS, percent | Two-year PFS, percent | Median PFS, months |
| 0 to 1 | 98 | 84 | 84 |
| 2 | 94 | 72 | 70 |
| 3 or more | 87 | 65 | 42 |
آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟
